EP. 13 Providing Support for Comorbidities and Psychological Health in Patients with Atopic Dermatitis
STAT6 Degradation by KT-621 Correlates With Itch and Lesion Reduction in ADByJared Gollob, MD,Kaitlyn Bader, Assistant Managing EditorJune 3rd 2026
Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD InterimByMaddi Hebebrand, MC, Associate EditorJune 1st 2026
Soquelitinib Demonstrates Efficacy in Atopic Dermatitis After Systemic FailureByAlbert Chiou, MD, MBA,Kaitlyn Bader, Assistant Managing EditorMay 28th 2026
Tips for Managing Pain and Local Skin Reactions During Photodynamic TherapyByNeal Bhatia, MD,Kaitlyn Bader, Assistant Managing EditorMay 27th 2026
Zumilokibart Meets Primary and Secondary Endpoints in Phase 2 AD TrialByMaddi Hebebrand, MC, Associate EditorMay 27th 2026